Prothena | PRTA - Assets


Prothena reported $302.58M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 95.64B 3.14B Jun/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Prothena USD 302.58M 47.32M Jun/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026